Healthcare


Healthcare Survey

Low awareness of GLP-1s globally, but high in the most advanced economies

Despite media discussions around the drugs, only around a third across 30 countries have heard about the drugs, with a lot of the discourse taking place via social media according to the Ipsos Health Service Report.
Healthcare Publication

Healthcare vs Evolution: Can GLP-1s Rewrite Our Evolutionary Story?

Our evolutionary tale began 6 million years ago, when humans were programmed to hoard calories in a world of scarcity. Today, that ancient wiring has become our greatest health risk.
Ipsos Update Publication

Ipsos Update - October 2024

Trends, News, Ageing … Ipsos Update explores the latest and research & thinking on key topics from Ipsos teams around the world.

Ipsos Update – September 2024

Data, Healthcare, Education … Ipsos Update explores the latest and research & thinking on key topics from Ipsos teams around the world.

Launch of Ipsos PersonaBot, a groundbreaking AI-powered solution to enhance segmentation research

Ipsos has launched Ipsos PersonaBot. This AI-powered tool, powered by Ipsos Facto, allows organizations to engage in conversations with personas representing their target audience. Ipsos PersonaBot is available for both consumer and healthcare sectors.
Healthcare Publication

Mastering complexity: The path towards a cancer-free reality

This is the third and final paper in a series which began eight years ago, focusing on unravelling – and ultimately overcoming – the sheer complexity of cancer, one of humanity’s oldest and most formidable foes.
Public Health Survey

Mental health is now the number one health problem, ahead of cancer and coronavirus

48% across 31 countries say the quality of the healthcare in their country is good – but the picture is inconsistent.
Healthcare Publication

The doctor-patient relationship in the generative AI era

Five reasons why the time to act for pharma is now.
Healthcare Publication

Oncology: the disease, dynamics & challenges of market research

The oncology treatment landscape rarely stands still, and its constant evolution affects all those involved – from patients and their carers to cancer treaters to the companies who manufacture and market treatments.